INMUNE BIO INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
INMUNE BIO INC. (INMB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $394.00K, a 16.70% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.02M, a 557.97% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $893.00K.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$170.00K, a 113.00% decline year-over-year.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $1.85M.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$1.36M, a 150.54% decline from fiscal 2023.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.69M, a 82.96% increase from fiscal 2022.
- INMUNE BIO INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.47M, a 33.50% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.62M 10-Q · filed 2026-08-06 | -$1.73M derived: sum of 3 quarters · filed 2026-08-06 | -$1.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$3.02M 10-Q · filed 2026-05-07 | -$2.13M derived: sum of 2 quarters · filed 2026-05-07 | -$2.29M derived: sum of 3 quarters · filed 2026-05-07 | -$1.82M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $893.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $723.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.20M derived: sum of 3 quarters · filed 2026-08-06 | $1.85M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $303.00K derived: sum of 2 quarters · filed 2026-08-06 | $962.00K 10-Q · filed 2025-10-30 | -$3.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.13M 10-Q · filed 2026-08-06 | -$2.92M derived: sum of 3 quarters · filed 2026-08-06 | -$1.61M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $659.00K 10-Q · filed 2026-05-07 | -$3.39M derived: sum of 2 quarters · filed 2026-05-07 | -$2.08M derived: sum of 3 quarters · filed 2026-05-07 | -$2.10M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$2.74M derived: sum of 2 quarters · filed 2026-03-30 | -$2.75M derived: sum of 3 quarters · filed 2026-03-30 | -$1.36M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.30M derived: sum of 2 quarters · filed 2025-10-30 | $2.69M 10-Q · filed 2025-10-30 | $6.92M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.38M 10-Q · filed 2025-08-07 | $5.61M derived: sum of 3 quarters · filed 2025-08-07 | $6.90M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $1.39M 10-Q · filed 2025-05-08 | $5.62M derived: sum of 2 quarters · filed 2025-05-08 | $6.91M derived: sum of 3 quarters · filed 2025-05-08 | $7.22M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.52M derived: sum of 2 quarters · filed 2025-03-27 | $5.82M derived: sum of 3 quarters · filed 2025-03-27 | $2.69M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.60M derived: sum of 2 quarters · filed 2024-10-31 | -$1.53M 10-Q · filed 2024-10-31 | $210.00K derived: sum of 4 quarters · filed 2024-10-31 | ||||
| 2023-06-30 | $308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.82M 10-Q · filed 2024-08-01 | -$1.08M derived: sum of 3 quarters · filed 2024-08-01 | $698.00K derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2023-03-31 | -$3.13M 10-Q · filed 2024-05-09 | -$1.39M derived: sum of 2 quarters · filed 2024-05-09 | $390.00K derived: sum of 3 quarters · filed 2024-05-09 | -$474.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.52M derived: sum of 2 quarters · filed 2024-03-28 | $2.65M derived: sum of 3 quarters · filed 2024-03-28 | $1.47M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $914.00K derived: sum of 2 quarters · filed 2023-11-01 | -$268.00K 10-Q · filed 2023-11-01 | -$756.00K derived: sum of 4 quarters · filed 2023-11-01 | ||||
| 2022-06-30 | -$864.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$2.05M 10-Q · filed 2023-08-07 | -$2.53M derived: sum of 3 quarters · filed 2023-08-07 | -$674.00K derived: sum of 4 quarters · filed 2023-08-07 | ||||
| 2022-03-31 | -$1.18M 10-Q · filed 2023-05-03 | -$1.67M derived: sum of 2 quarters · filed 2023-05-03 | $190.00K derived: sum of 3 quarters · filed 2023-05-03 | $979.00K derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2021-12-31 | -$488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.37M derived: sum of 2 quarters · filed 2023-03-02 | $2.16M derived: sum of 3 quarters · filed 2023-03-02 | $2.21M 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $2.65M derived: sum of 2 quarters · filed 2022-11-02 | $2.70M 10-Q · filed 2022-11-02 | $3.03M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $789.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $843.00K 10-Q · filed 2022-08-03 | $1.17M derived: sum of 3 quarters · filed 2022-08-03 | $1.74M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $54.00K 10-Q · filed 2022-05-05 | $382.00K derived: sum of 2 quarters · filed 2022-05-05 | $947.00K derived: sum of 3 quarters · filed 2022-05-05 | $876.00K derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $893.00K derived: sum of 2 quarters · filed 2022-03-03 | $822.00K derived: sum of 3 quarters · filed 2022-03-03 | $1.12M 10-K · filed 2022-03-03 | $1.12M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $565.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $494.00K derived: sum of 2 quarters · filed 2021-11-03 | $788.00K 10-Q · filed 2021-11-03 | $789.10K 10-Q · filed 2020-11-05 | $852.75K derived: sum of 4 quarters · filed 2021-11-03 | |||
| 2020-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $223.00K 10-Q · filed 2021-08-04 | $222.90K 10-Q · filed 2020-08-05 | $287.75K derived: sum of 3 quarters · filed 2021-08-04 | $186.77K derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | $294.00K 10-Q · filed 2021-05-05 | $293.67K 10-Q · filed 2020-05-14 | $358.75K derived: sum of 2 quarters · filed 2021-05-05 | $257.77K derived: sum of 3 quarters · filed 2021-05-05 | $316.74K derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $64.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$36.23K derived: sum of 2 quarters · filed 2021-03-04 | $22.74K derived: sum of 3 quarters · filed 2021-03-04 | -$151.23K 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | -$100.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$42.01K derived: sum of 2 quarters · filed 2020-11-05 | -$215.98K 10-Q · filed 2020-11-05 | $147.62K derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $58.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$115.00K 10-Q · filed 2020-08-05 | -$376.53K 10-Q · filed 2019-08-09 | $248.59K derived: sum of 3 quarters · filed 2020-08-05 | $289.43K derived: sum of 4 quarters · filed 2020-08-05 | |||
| 2019-03-31 | -$173.97K 10-Q · filed 2020-05-14 | -$343.11K 10-Q · filed 2019-05-15 | $189.62K derived: sum of 2 quarters · filed 2020-05-14 | $230.46K derived: sum of 3 quarters · filed 2020-05-14 | $192.79K derived: sum of 4 quarters · filed 2020-05-14 | |||
| 2018-12-31 | $363.60K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $404.43K derived: sum of 2 quarters · filed 2020-03-11 | $366.76K derived: sum of 3 quarters · filed 2020-03-11 | $426.96K 10-K · filed 2020-03-11 | $688.49K 10-K · filed 2019-03-29 | |||
| 2018-09-30 | $40.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $3.17K derived: sum of 2 quarters · filed 2019-11-08 | $63.37K 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | -$37.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $22.53K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $60.20K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $68.55K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |